Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
PROK
PROK
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
PROK News
Chronic Kidney Disease Market Growth Drivers
Mar 03 2026
Newsfilter
Avant Technologies Drives 67.5% Market Share in Cell Therapy Manufacturing
Dec 16 2025
PRnewswire
Avant Technologies Drives 67.5% Market Share in Cell Therapy Manufacturing
Dec 16 2025
Newsfilter
PROKIDNEY CORP. Reports Smaller Q3 Loss, Surpassing Expectations
Nov 11 2025
NASDAQ.COM
ProKidney Announces Financial Results for Q3 2025 Along with Regulatory and Clinical Updates
Nov 10 2025
Newsfilter
ProKidney Unveils Comprehensive Findings from Phase 2 REGEN-007 Trial of Rilparencel at the 2025 American Society of Nephrology Kidney Week
Nov 06 2025
Newsfilter
ProKidney Reveals Two Abstracts Chosen for Presentation at the 2025 Kidney Week of the American Society of Nephrology
Oct 20 2025
Newsfilter
ProKidney Corp. (PROK) Shares Insights at Citi's Biopharma Back to School Conference Transcript
Sep 03 2025
Newsfilter
ProKidney to Attend Citi Biopharma Back to School Conference and Morgan Stanley Global Healthcare Conference
Aug 27 2025
Newsfilter
Forecast: Chamath Palihapitiya's $250 Million SPAC May Develop the Next Palantir for the U.S. Energy Grid
Aug 24 2025
NASDAQ.COM
Chamath Palihapitiya Reenters SPAC Market: Previous 18 Deals Show Average Loss of 14%
Aug 19 2025
Benzinga
Palihapitiya cautions against emotional reactions in the casino while introducing a new SPAC.
Aug 19 2025
MarketWatch
ProKidney Reports 78 Percent Gain in Q2
Aug 13 2025
NASDAQ.COM
JP Morgan Maintains a Neutral Stance on ProKidney Corp. (PROK)
Jul 20 2025
Yahoo Finance
ProKidney Secures FDA Alignment On Accelerated Approval Pathway For Rilparencel
Jul 15 2025
NASDAQ.COM
Simulations Plus, FB Financial And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Jul 15 2025
Benzinga
Show More News
